Traditional approaches to androgen deprivation therapy

Urology

Volumn 78, Issue 5 SUPPL., 2011, Pages

  Moul, Judd W ^a   Evans, Christopher P ^b   Gomella, Leonard G ^c   Roach III, MacK ^d,e   Dreicer, Robert ^f,g  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 80755129141     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.051     Document Type: Article

References (50)

1. C. Huggins, R.E.J. Stevens, and C.V. Hodges Studies in prostatic cancer II The effects of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
2. D.J. Samson, J. Seidenfeld, and B. Schmitt Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376 (Pubitemid 34787603)
3. D.A. Loblaw, K.S. Virgo, and R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline J Clin Oncol 25 2007 1596 1605 (Pubitemid 46733088)
4. S.J. Freedland Screening, risk assessment, and the approach to therapy in patients with prostate Cancer 117 2011 1123 1135
5. A.V. D'Amico, R. Whittington, and Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
6. A.V. D'Amico, J.W. Moul, and P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383 (Pubitemid 37220457)
7. S.R. Harlan, M.R. Cooperberg, and E.P. Elkin Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE J Urol 170 2003 1804 1807 (Pubitemid 37254932)
8. R.K. Valicenti, L.G. Gomella, and El-Gabry The multidisciplinary clinic approach to prostate cancer counseling and treatment Semin Urol Oncol 18 2000 188 191 (Pubitemid 30666281)
9. L.G. Gomella, J. Lin, and J. Hoffman-Censits Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience J Oncol Pract 6 2010 e35 e37
10. S.A. Brassell, A. Dobi, and G. Petrovics The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research Urol Oncol 27 2009 562 569
11. S.M.H. Alibhai, S. Gogov, and Z. Allibhai Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review Crit Rev Oncol/Hematol 60 2006 201 215 (Pubitemid 44709617)
12. F. Labrie, L. Cusan, and P. Diamond Down staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone releasing hormone agonist Urology 44 1994 29 37 (Pubitemid 124019793)
13. M.S. Soloway, K. Pareek, and R. Sharifi Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results J Urol 167 2002 112 116 (Pubitemid 34024512)
14. G. Aus, P.A. Abrahamsson, and G. Ahlgren Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial BJU Int 90 2002 561 566
15. M.E. Gleave, S.L. Goldenberg, J.L. Chin Canadian Uro-Oncology Group Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects J Urol 166 2001 500 506 (Pubitemid 32652231)
16. M. Roach III Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer Rev Urol 6 suppl 8 2004 S24 S31
17. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 8610 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
18. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 9202 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
19. J.M.L. Kaminski, A.L. Hanlon, and D.L. Joon Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth Int J Radiat Oncol Biol Phys 57 2003 24 28 (Pubitemid 36959735)
20. A. Pollack, N. Salem, and F. Ashorri Lack of prostate cancer radiosensitization by androgen deprivation Int J Radiat Oncol Biol Phys 51 2001 1002 1007 (Pubitemid 33026431)
21. J. Laverdire, J.L. Gomez, and L. Cusan Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252 (Pubitemid 27138705)
22. J. Laverdire, A. Nabid, and L.D. De Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140 (Pubitemid 38327543)
23. Radiation Therapy Oncology Group, RTOG 0815 A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer Accessed http://www.rtog.org/members/protocols/0815/0815.pdf
24. M. Roach, R. Valicenti, and S.O. Asbell Whole pelvic, "mini-pelvic" or prostate only external beam radiotherapy field following neoadjuvant and concurrent hormonal therapy: in patients treated on RTOG Int J Radiol Biol Phys 9413 2006 66:647-653
25. M. Roach, M.L. DeSilvio, and C. Lawton Phase III Trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
26. M. Roach To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials J Clin Oncol 28 2010 450 452
27. L. Potters, T. Torre, and R. Ashley Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy J Clin Oncol 18 2000 1187 1192 (Pubitemid 30159835)
28. D.C. Beyer, and D.G. Brachman Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy Radiother Oncol 57 2000 263 267
29. C. King, J. Sanzone, and K. Anderson Definitive therapy for stage T1/T2 prostate carcinoma: PSA-based comparison between surgery, external beam, and implant radiotherapy J Brachyther Int 14 1998 169 177 (Pubitemid 28420607)
30. G.S. Merrick, W.M. Butler, and K.E. Wallner Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 61 2005 32 43 (Pubitemid 40039102)
31. K.E. Wallner, J. Blasko, and M.J.eds Dattoli Prostate Brachytherapy: Therapy Made Complicated Seattle, WA: Smart Medicine Publishing Group 1997 1411415
32. D. McGowan, D. Hunt, and C. Jones Effect of short-term endocrine therapy prior to and during radiation therapy on overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA equal to or less than 20: initial results of RTOG 94-08 American Society of Clinical Oncology (ASCO); 2010 Genitourinary Cancers Symposium. Abstract 6. Presented March 5, 2010 Accessed http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=73&abstractID=30652
33. M. Mercader, B.K. Bodner, and M.T. Moser T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci USA 98 2001 14565 14570 (Pubitemid 33121432)
34. M.V. Pilepich, R. Caplan, and R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31 J Clin Oncol 15 1997 1013 1021 (Pubitemid 27106285)
35. M. Roach, J. Lu, and M.V. Pilepich Predicting long-term survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627 (Pubitemid 30317479)
36. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
37. F.E. Calais da Silva, A.V. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
38. M. Hussain, C.M. Tangen, and C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990 (Pubitemid 46630748)
39. U. Tunn Can intermittent hormone therapy fulfill its promise? Eur Urol 7 2008 752 757
40. E.Y. Yu, R. Gulati, and D. Telesca Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation J Clin Oncol 28 2010 2668 2673
41. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80 (Pubitemid 350166735)
42. J.E. Faris, and M.R. Smith Metabolic sequelae associated with androgen deprivation therapy for prostate cancer Curr Opin Endocrinol Diabetes Obes 17 2010 240 246
43. D.P. Byar, and D.K. Corie Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies NCI Monogr 7 1988 165 170
44. The Medical Research Council, Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial Br J Urol 79 1997 235 246
45. E.M. Messing, J. Manola, and M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
46. J.W. Moul, and G. Chodak Combination hormonal therapy: a reassessment within advanced prostate cancer Prostate Cancer Prostatic Dis 7 2004 S2 S7
47. U.E. Studer, P. Whelan, and W. Albrecht Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876 (Pubitemid 46638985)
48. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425 (Pubitemid 46999213)
49. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology CA Cancer J Clin 60 2010 194 201
50. J. Irani, L. Salomon, and R. Oba Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial Lancet Oncol 11 2010 147 154